Professor Dean WilliamsLAILA DURHUB MOHAMMED ALSHAMMARI2022-05-262022-05-26https://drepo.sdl.edu.sa/handle/20.500.14154/33638Liver fibrosis commonly occurs as a liver’s reaction to a persistent injury. Some of the significant causes of LF include hepatitis and alcohol ingestion. The primary intention of this exploration was to deduce the development of the potential therapeutic agents that can be effective in managing patients diagnosed with hepatic fibrosis. The exploration involved a systematic qualitative review of one hundred and twenty articles outsourced from five major databases, namely, Web of Science, Science Direct, PubMed, Cochrane Library, and the BMC. A review of the articles aimed at unveiling the drugs that are potent in treating hepatic fibrosis in humans. The outcomes of the investigation revealed that even though many studies exist on some of the drugs that show antifibrotic effects, few trials involved human models. As such, there is a need to carry out more explorations on the agents that demonstrate antifibrotic potential on animal models. The most operational way of managing patients who present with hepatic fibrosis is treating the triggering factor, such as giving antivirals for viral hepatitis.en